



Certification Page Regular and Emergency Rules

Revised August 2023

☒ **Emergency Rules** (Complete Sections 1-3 and 5-6)

☐ **Regular Rules**

1. General Information

a. Agency/Board Name*

Attorney General (in his capacity as Commissioner of Drugs and Substances Control)

b. Agency/Board Address

109 State Capitol

c. City

Cheyenne

d. Zip Code

82002

e. Name of Agency Liaison

Jenny L. Craig

f. Agency Liaison Telephone Number

(307) 777-7977

g. Agency Liaison Email Address

jenny.craig1@wyo.gov

h. Adoption Date

04/16/2026

i. Program

Schedule I - Controlled Substances

Amended Program Name (if applicable):

* ☐ By checking this box, the agency is indicating it is exempt from certain sections of the Administrative Procedure Act including public comment period requirements. Please contact the agency for details regarding these rules.

2. Legislative Enactment For purposes of this Section 2, "new" only applies to regular (non-emergency) rules promulgated in response to a Wyoming legislative enactment not previously addressed in whole or in part by prior rulemaking and does not include rules adopted in response to a federal mandate.

a. Are these non-emergency or regular rules new as per the above description and the definition of "new" in Chapter 1 of the Rules on Rules?



No.



Yes.

If the rules are new, please provide the Legislative Chapter Number and Year Enacted:

Chapter:

Year:

3. Rule Type and Information For purposes of this Section 3, "New" means an emergency or regular rule that has never been previously created.

a. Provide the Chapter Number, Title* and Proposed Action for Each Chapter. Please use the "Additional Rule Information" form to identify additional rule chapters.

Chapter Number:

1

Chapter Name:

Additional Controlled Substances

☐ New

☒ Amended

☐ Repealed

Amended Chapter Name (if applicable):

Chapter Number:

Chapter Name:

☐ New

☐ Amended

☐ Repealed

Amended Chapter Name (if applicable):

Chapter Number:

Chapter Name:

☐ New

☐ Amended

☐ Repealed

Amended Chapter Name (if applicable):

Chapter Number:

Chapter Name:

☐ New

☐ Amended

☐ Repealed

Amended Chapter Name (if applicable):

Chapter Number:

Chapter Name:

☐ New

☐ Amended

☐ Repealed

Amended Chapter Name (if applicable):

Chapter Number:

Chapter Name:

☐ New

☐ Amended

☐ Repealed

Amended Chapter Name (if applicable):

4. Public Notice of Intended Rulemaking

a. Notice was mailed 45 days in advance to all persons who made a timely request for advance notice. ☐ No. ☐ Yes. ☐ N/A

b. A public hearing was held on the proposed rules. ☐ No. ☐ Yes. Please complete the boxes below.

Date:	Time:	City:	Location:

5. Checklist


a. ☐ For regular rules, the Statement of Principal Reasons is attached to this Certification and, in compliance with Tri-State Generation and Transmission Association, Inc. v. Environmental Quality Council, 590 P.2d 1324 (Wyo. 1979), includes a brief statement of the substance or terms of the rule and the basis and purpose of the rule

b. ☒ For emergency rules, the Memorandum to the Governor documenting the emergency, which requires promulgation of these rules without providing notice or an opportunity for a public hearing, is attached to this Certification.

6. Agency/Board Certification

The undersigned certifies that the foregoing information is correct. By electronically submitting the emergency or regular rules into the Wyoming Administrative Rules System, the undersigned acknowledges that the Registrar of Rules will review the rules as to form and, if approved, the electronic filing system will electronically notify the Governor's Office, Attorney General's Office, and Legislative Service Office of the approval and electronically provide them with a copy of the complete rule packet on the date approved by the Registrar of Rules. The complete rules packet includes this signed certification page; the Statement of Principal Reasons or, if emergency rules, the Memorandum to the Governor documenting the emergency; and a strike and underscore copy and clean copy of each chapter of rules.

Signature of Authorized Individual



Printed Name of Signatory

Keith G. Kautz

Signatory Title

Attorney General

Date of Signature

04/16/2026

7. Governor's Certification

I have reviewed these rules and determined that they:

1. Are within the scope of the statutory authority delegated to the adopting agency;
2. Appear to be within the scope of the legislative purpose of the statutory authority; and, if emergency rules,
3. Are necessary and that I concur in the finding that they are an emergency.

Therefore, I approve the same.

Governor's Signature

Date of Signature



Office of the Attorney General

Governor
Mark Gordon

Attorney General
Keith G. Kautz

Criminal Division
109 State Capitol
Cheyenne, Wyoming 82002
307-777-7977 Telephone
307-777-5034 Fax

Chief Deputy Attorney General
Ryan Schelhaas

Division Deputy
Jenny L. Craig

MEMORANDUM

DATE: April 16, 2026

TO: The Honorable Mark Gordon, Governor

FROM: Keith G. Kautz, Wyoming Attorney General (The agency contact person is Jenny L. Craig, whose telephone number is 777-6862 and e-mail address is jenny.craig1@wyo.gov.)

SUBJECT: Emergency Rules and Regulations

PRIORITY: **High.** This emergency rule should be filed as soon as possible.

Under Wyo. Stat. Ann. § 35-7-1011(a), the Wyoming Attorney General, as the designated Commissioner of Drugs and Substances Control, may add substances to or delete or reschedule all substances enumerated in the schedules in Wyo. Stat. Ann. §§ 35-7-1014, 35-7-1016, 35-7-1018, 35-7-1020 and 35-7-1022. Further, under Wyo. Stat. Ann. § 35-7-1011(d), the Wyoming Attorney General is required to designate substances as controlled substances through the promulgation of an emergency rule within 30 days of the United States Drug Enforcement Administration (DEA) designating a substance as a controlled substance.

The Wyoming Attorney General is adding 4-fluoroamphetamine, bromazepam, and 3-MeO-PCP to Schedule I (Wyo. Stat. Ann. § 35-7-1014) of the Wyoming Controlled Substances Act of 1971 through an emergency rule. This action is being taken in response to orders issued by the DEA. *See* Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I, 91 Fed. Reg. 1692 (January 15, 2026) (codified at 21 C.F.R. pt. 1308); Schedules of Controlled Substances: Temporary Placement of Bromazepam in Schedule I, 91 Fed. Reg. 12504 (March 16, 2026) (codified at 21 C.F.R. pt. 1308); Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I, 91

Honorable Mark Gordon

April 16, 2026

Page 2 of 2

Fed. Reg. 13733 (March 23, 2026) (codified at 21 C.F.R. pt. 1308). These orders added 4-fluoroamphetamine, bromazolam, and 3-MeO-PCP to Schedule I of the Controlled Substances Act. 21 U.S.C. § 801 *et seq.*

At the time the DEA issued its January and March orders, the Wyoming Attorney General was already engaged in the rule-making process regarding a previous DEA change to Schedule I. Therefore, the Wyoming Attorney General took action to amend Schedule I as soon as it was possible. The adopted rule does not exceed the requirements of the federal regulations. Contemporaneous with the filing of this emergency rule, the Wyoming Attorney General is promulgating a permanent rule through the rule-making process.

Enclosed is the emergency rule packet.

Should you or your staff have any questions regarding this information, please do not hesitate to contact this Office.

STATEMENT OF PRINCIPAL REASONS

Schedule I – Controlled Substances Chapter 1: Additional Controlled Substances

Under Wyo. Stat. Ann. § 35-7-1011(a), the Wyoming Attorney General, as the designated Commissioner of Drugs and Substances Control, may add substances to or delete or reschedule all substances enumerated in the schedules in Wyo. Stat. Ann. §§ 35-7-1014, 35-7-1016, 35-7-1018, 35-7-1020 and 35-7-1022. Further, under Wyo. Stat. Ann. § 35-7-1011(d), the Wyoming Attorney General is required to designate substances as controlled substances through the promulgation of an emergency rule within 30 days of the United States Drug Enforcement Administration (DEA) designating a substance as a controlled substance.

The Wyoming Attorney General is adding 4-fluoroamphetamine, bromazolam, and 3-MeO-PCP to Schedule I (Wyo. Stat. Ann. § 35-7-1014) of the Wyoming Controlled Substances Act of 1971 through an emergency rule. This action is being taken in response to orders issued by the DEA. *See* Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I, 91 Fed. Reg. 1692 (January 15, 2026) (codified at 21 C.F.R. pt. 1308); Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I, 91 Fed. Reg. 12504 (March 16, 2026) (codified at 21 C.F.R. pt. 1308); Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I, 91 Fed. Reg. 13733 (March 23, 2026) (codified at 21 C.F.R. pt. 1308). These orders added 4-fluoroamphetamine, bromazolam, and 3-MeO-PCP to Schedule I of the Controlled Substances Act. 21 U.S.C. § 801 *et seq.*

At the time the DEA issued its January and March orders, the Wyoming Attorney General was already engaged in the rule-making process regarding a previous DEA change to Schedule I. Therefore, the Wyoming Attorney General took action to amend Schedule I as soon as it was possible. The adopted rule does not exceed the requirements of the federal regulations. Contemporaneous with the filing of this emergency rule, the Wyoming Attorney General is promulgating a permanent rule through the rule-making process.

Chapter 1

Additional Controlled Substances

Emergency rules are in effect no longer than 120 days after filing with the Registrar of Rules.

Section 1. Purpose. The purpose of these rules is to add, delete, and reschedule controlled substances in the Wyoming Controlled Substances Act of 1971. Some changes will be made to similarly control a substance in response to the publication of a final order in the Federal Register designating that substance as a controlled substance under federal law. Other changes will be made at the discretion of the Wyoming Attorney General, in his or her capacity as the Commissioner of Drugs and Substances Control, with the advice of the Advisory Board on Drugs and Substances Control.

Section 2. Authority. The Commissioner of Drugs and Substances Control's rulemaking authority is found at Wyoming Statute § 35-7-1011(a) and (d), which allow the Commissioner to add, delete, and reschedule substances to the control schedules pursuant to the procedures of the Wyoming Administrative Procedure Act.

Section 3. Additional Controlled Substances. The Commissioner of Drugs and Substances Control adds the following substances to Schedule I:

- (a) Synthetic cannabinoids:
 - (i) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, commonly known as 5F-AMB, and its isomers, ethers, salts, and salts of isomers, esters, and ethers;
 - (ii) [N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide, commonly known as ADB-FUBINACA;
 - (iii) [Methyl 2-({ 1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate], commonly known as FUB-AMB;
 - (iv) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, commonly known as NM2201; CBL2201, and its isomers, ethers, salts, and salts of isomers, esters, and ethers;
 - (v) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 4-CN-CUMYL-BUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA; CUMYL-4CN-BINACA; SGT-78, and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(vi) methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-CHMICA, AMB-CHMICA, and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(vii) 1-(5-fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*-pyrrolo[2,3-*b*]pyridine-3-carboxamide, commonly known as 5F-CUMYL-P7AICA, and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(viii) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide, commonly known as MAB-CHMINACA or ADB-CHMINACA, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible;

(ix) methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-ADB or 5F-MDMB-PINACA;

(x) methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as MDMB-CHMICA or MMB-CHMINACA;

(xi) methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as MDMB-FUBINACA;

(xii) ethyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-EDMB-PINACA, and its optical, positional, and geometric isomers, salts, and salts of isomers;

(xiii) methyl 2-(1-(5-fluoropentyl)-1*H*-indole-3-carboxamido)-3,3-dimethylbutanoate commonly known as 5F-MDMB-PICA, and its optical, positional, and geometric isomers, salts, and salts of isomers;

(xiv) *N*-(adamantan-1-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamide, commonly known as FUB-AKB48; FUB-APINACA; AKB48 *N*-(4-FLUOROBENZYL), and its optical, positional, and geometric isomers, salts, and salts of isomers;

(xv) 1-(5-fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*-indazole-3-carboxamide commonly known as 5F-CUMYL-PINACA; SGT-25, and its optical, positional, and geometric isomers, salts, and salts of isomers;

(xvi) (1-(4-fluorobenzyl)-1*H*-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone commonly known as FUB-144, and its optical, positional, and geometric isomers, salts, and salts of isomers;

(xvii) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1*H*-indazole-3-carboxamide (other name: 5F-AB-PINACA) and its salts, isomers, and salts of isomers;

(xviii) methyl 2-(1-(4-fluorobutyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate (other name: 4F-MDMB-BINACA, 4F-MDMB-BUTINACA) and its salts, isomers, and salts of isomers;

(xix) methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1*H*-indazole-3-carboxamido)butanoate (other name: MDMB-4en-PINACA) and its optical and geometric isomers, salts, and salts of isomers, whenever the existence of such isomers and salts is possible;

(xx) methyl 2-[[1-(4-fluorobutyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (other names: 4F-MDMB-BUTICA; 4F-MDMB-BICA) and its optical and geometric isomers, salts, and salts of isomers, whenever the existence of such isomers and salts is possible;

(xxi) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1-yl)-1*H*-indazole-3-carboxamide (other name: ADB-4en-PINACA) and its optical and geometric isomers, salts, and salts of isomers, whenever the existence of such isomers and salts is possible;

(xxii) 5-Pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-*b*]indol-1-one (other names: CUMYL-PEGACLONE; SGT—151) and its optical and geometric isomers, salts, and salts of isomers, whenever the existence of such isomers and salts is possible;

(xxiii) ethyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (other names: 5F-EDMB-PICA; 5F-EDMB-2201) and its optical and geometric isomers, salts, and salts of isomers, whenever the existence of such isomers and salts is possible; and

(xiv) methyl 2-(1-(4-fluorobenzyl)-1*H*-indole-3-carboxamido)-3-methylbutanoate (other name: MMB-FUBICA) and its optical and geometric isomers, salts, and salts of isomers, whenever the existence of such isomers and salts is possible.

(b) Synthetic opioid analgesics:

(i) trans-3,4-dichloro-*N*-[2-dimethylamino)cyclohexyl]-*N*-methylbenzamide, commonly known as U-47700;

(ii) para-fluorobutyryl fentanyl, commonly known as p-FBF;

(iii) *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacetamide, commonly known as acetyl fentanyl;

(iv) 3,4-dichloro-*N*-[(1dimethylamino)cyclohexylmethyl]benzamide), commonly known as AH-7921;

(v) Cyclopentyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylcyclopentanecarboxamine) including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(vi) Isobutyryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylisobutyramide) including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(vii) *para*-Chloroisobutyryl fentanyl (*N*-(4-chlorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide) including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(viii) *para*-Methoxybutyryl fentanyl (*N*-(4-methoxyphenyl)-*N*-(1-phenethylpiperidin-4-yl)butyramide) including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible; and

(ix) Valeryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylpentanamide) including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible.

(c) Analgesics:

(i) 4-chloro-*N*-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-benzenesulfonamide, commonly known as W-18.

(d) Synthetic opioids:

(i) *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutyramide, also known as *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutanamide, (commonly known as butyryl fentanyl);

(ii) *N*-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-*N*-phenylpropionamide, also known as *N*-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-*N*-phenylpropanamide, (commonly known as beta-hydroxythiofentanyl) and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(iii) *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylfuran-2-carboxamide, (commonly known as furanyl fentanyl) and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(iv) *para*-fluoroisobutyryl fentanyl [*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide] (commonly known as 4-fluoroisobutyryl fentanyl) and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(v) acryloylfentanyl [*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacrylamide], (commonly known as acryl fentanyl) and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(vi) [N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide], (commonly known as tetrahydrofuranyl fentanyl) and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(vii) [N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide], (commonly known as ocfentanil) and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(viii) Cyclopropyl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide] and its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;

(ix) Methoxyacetyl fentanyl [2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide] and its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;

(x) *ortho*-Fluorofentanyl [N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide] (also known as 2-fluorofentanyl) and its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;

(xi) *para*-Fluorobutyl fentanyl [N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide] and its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;

(xii) Fentanyl related substances that are not currently listed in any schedule of the Wyoming Controlled Substances Act and their isomers, ethers, salts, and salts of isomers, esters, and ethers;

(xiii) *N, N*-diethyl-2-[2-(4 isopropoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl]ethan-1-amine (commonly known as isotornitazene), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xiv) Crotonyl fentanyl [(*E*)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide];

(xv) 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2*H*-benzo[*d*]imidazole-2-one, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other names: bromphine; 1-[1-[1-(4-bromophenyl)ethyl]-4-piperidinyl]-1,3-dihydro-2*H*-benzimidazol-2-one);

(xvi) *beta*-Methyl fentanyl (*N*-phenyl-*N*-(1-(2-phenylpropyl)piperidin-4-yl)propionamide; also known as β -methyl fentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xvii) *beta'*-Phenyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*,3-diphenylpropanamide; also known as β' -phenyl fentanyl; 3-phenylpropanoyl fentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xviii) 2'-Fluoro *ortho*-fluorofentanyl (*N*-(1-(2-fluorophenethyl)piperidin-4-yl)-*N*-(2-fluorophenyl)propionamide; also known as 2'-fluoro 2-fluorofentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xix) 4'-Methyl acetyl fentanyl (*N*-(1-(4-methylphenethyl)piperidin-4-yl)-*N*-phenylacetamide) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xx) *ortho*-Fluorobutyryl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)butyramide; also known as 2-fluorobutyryl fentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxi) *ortho*-Methyl acetylfentanyl (*N*-(2-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)acetamide; also known as 2-methyl acetylfentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxii) *ortho*-Methyl methoxyacetyl fentanyl (2-methoxy-*N*-(2-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)acetamide; also known as 2-methyl methoxyacetyl fentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxiii) *para*-Methylfentanyl (*N*-(4-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)propionamide; also known as 4-methylfentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxiv) Phenyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbenzamide; also known as benzoyl fentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxv) Thiofuranyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylthiophene-2-carboxamide; also known as 2-thiofuranyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxvi) Fentanyl carbamate (ethyl (1-phenethylpiperidin-4-yl)(phenyl)carbamate) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxvii) *ortho*-Fluoroacryl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)acrylamide) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxviii) *ortho*-Fluoroisobutyryl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxix) *para*-Fluoro furanyl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)furan-2-carboxamide) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxx) 2-(2-(4-butoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (other name: Butonitazene);

(xxxi) 2-(2-(4-ethoxybenzyl)-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: Etodesnitazene; etazene);

(xxxii) *N,N*-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Flunitazene);

(xxxiii) *N,N*-diethyl-2-(2-(4-methoxybenzyl)-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Metodesnitazene);

(xxxiv) *N,N*-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Metonitazene);

(xxxv) 2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1*H*-benzimidazole, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: *N*-pyrrolidino etonitazene; etonitazepyne);

(xxxvi) *N,N*-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Protonitazene);

(xxxvii) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation;

(xxxviii) *meta*-fluorofentanyl (*N*-(3-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)propionamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xxxix) *meta*-fluoroisobutyl fentanyl (*N*-(3-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xl) *para*-methoxyfentanyl fentanyl (*N*-(4-methoxyphenyl)-*N*-(1-phenethylpiperidin-4-yl)furan-2-carboxamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xli) 3-furanyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylfuran-3-carboxamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xlii) 2',5'-dimethoxyfentanyl (*N*-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-*N*-phenylpropionamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xliii) isovaleryl fentanyl (3-methyl-*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutanamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xliv) *ortho*-fluorofuranyl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)furan-2-carboxamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xlv) *alpha*'-methyl butyryl fentanyl (2-methyl-*N*-(1-phenethylpiperidin-4-yl)-*N*-penylbutanamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xlvi) *para*-methylcyclopropyl fentanyl (*N*-(4-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xlvii) 1-(2-methyl-4(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one (commonly known as 2-methyl AP-237), including its optical and geometric isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xlviii) 2-(4-methoxybenzyl)-5-nitro-1-(2-(pyrrolidine-1-yl)-1*H*-benzimidazole, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: *N*-pyrrolidino metonitazene; metonitazepyne);

(xlix) 5-nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidine-1-yl)ethyl)-1*H*-benzimidazole, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: *N*-pyrrolidino protonitazene; protonitazepyne);

(l) *N*-ethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: *N*-desethyl isotonitazene);

(li) 2-(4-ethoxybenzyl)-5-nitro-1-(2-(piperidin-1-yl)ethyl)-1*H*-benzimidazole, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: *N*-piperidinyl etonitazene; etonitazepipine);

(lii) 2-(2-((2,3-dihydrobenzofuran-5-yl)methyl)-5-nitro-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Ethyleneoxynitazene);

(liii) 2-(2-(benzodioxol-5-ylmethyl)-5-nitro-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: Methylenedioxyntazene; 3',4'-methylenedioxyntazene);

(liv) 2-(2-(4-ethoxybenzyl)-5-methyl-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: 5-methyl etodesnitazene);

(lv) 2-(2-(4-ethoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)-*N*-ethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: *N*-desethyl etonitazene);

(lvi) *N*-ethyl-2-(5-nitro-2-(4-propoxybenzyl)-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: *N*-desethyl protonitazene);

(lvii) 2-(2-(4-ethoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)-*N,N*-dimethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other Name: *N,N*-dimethylamino etonitazene); and

(lviii) 2-(4-isopropoxybenzyl)-5-nitro-1-(20(pyrrolidine-1-yl)ethyl)-1*H*-benzimidazole, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: *N*-pyrrolidino isotonitazene).

(e) Synthetic cathinone:

(i) *N*-1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone, commonly known as *N*-ethylpentylone, ephylone, and its optical, positional, and geometric isomers, salts, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible;

(ii) *N*-Ethylhexedrone (other name: 2-(ethylamino)-1-phenylhexan-1-one) and its optical, positional, and geometric isomers, salts, and salts of isomers;

(iii) alpha-Pyrrolidinohexanophenone (other names: a-PHP; alpha-pyrrolidinohexiophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one) and its optical, positional, and geometric isomers, salts, and salts of isomers;

(iv) 4-Methyl-alpha-ethylaminopentiophenone (other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one) and its optical, positional, and geometric isomers, salts, and salts of isomers;

(v) 4'-Methyl-alpha-pyrrolidinohephenone (other names: MPHP; 4'-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)heptan-1-one) and its optical, positional, and geometric isomers, salts, and salts of isomers;

(vi) alpha-Pyrrolidinoheptaphenone (other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one) and its optical, positional, and geometric isomers, salts, and salts of isomers;

(vii) 4'-Chloro-alpha-pyrrolidinovalerophenone (other names: 4-chloro-a-PVP; 4'-chloro-alpha-pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one) and its optical, positional, and geometric isomers, salts, and salts of isomers;

(viii) 4-methyl-N-ethylcathinon (other name: 4-MEC) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(ix) 4-methyl-alpha-pyrrolidinopropiophenone (other name: 4-MePPP) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(x) alpha-pyrrolidinopentiophenone (other name: α -PVP) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(xi) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (other names: butylone, bk-MBDB) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(xii) 2-(methylamino)-1-phenylpentan-1-one (other name: pentedron) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(xiii) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (other names: pentylone, bk-MBDP) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(xiv) 4-fluoro-N-methylcathinone (other names: 4-FMC, flephedrone) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(xv) 3-fluoro-N-methylcathinone (other name: 3-FMC) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(xvi) 1-(naphthalene-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (other name: naphyrone) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible; and

(xvii) alpha-pyrrolidinobutiophenon (other name: α -PBP) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible.

(f) Hallucinogenic substances:

(i) 1-(4-methoxyphenyl)-*N*-methylpropan-2-amine (other names: *para*-methoxymethamphetamine, PMMA), including its salts, isomers, and salts of isomers;

(ii) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine, MXE);

(iii) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one (other names: eutylone; bk-EBDB);

(iv) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1*H*-indazole-3-carboxamide (also known as ADB-BUTINACA), including its salts, isomers, and salts of isomers;

(v) 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (also known as α -PiHP or *alpha*-PiHP), including its salts, isomers, and salts of isomers;

(vi) 2-(methylamino)-1-(3-methylphenyl)propan-1-one (also known as 3-MMC or 3-methylmethcathinone), including its salts, isomers, and salts of isomers;

(vii) 4-Chloromethcathinone (also known as 4—CMC or 1-(4-chlorophenyl)-2-(methylamino)propan-1-one), including its salts, isomers, and salts of isomers; and

(viii) 3-methoxyphencyclidine (other names: 1-(1-(3-methoxyphenyl)cyclohexyl)piperidine; 3-MeO-PCP), including its salts, isomers, and salts of isomers.

(g) Stimulants:

(i) 4,4'-Dimethylaminorex (common name 4,4'-DMAR; other names 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine);

(ii) Amineptine (7-[(10,11-dihydro-5*H*-dibenzo[*a,d*]cyclohepten-5-yl)amino]heptanoic acid), including its salts, isomers, and salts of isomers;

(iii) Mesocarb (*N*-phenyl-*N'*-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate), including its salts, isomers, and salts of isomers;

(iv) Methiopropamine (*N*-methyl-1-(thiophen-2-yl)propan-2-amine), including its salts, isomers, and salts of isomers;

(v) Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate), including its salts, isomers, and salts of isomers; and

(vi) 4-Fluoroamphetamine (4-FA, 1-(4-fluorophenyl)propan-2-amine, *para*-fluoroamphetamine, including its salts, isomers, and salts of isomers.

(h) Depressants:

(i) 4-(2-chlorophenyl)-2-ethyl-9-methyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*α*][1,4]diazepine (other name: etizolam), its salts, isomers, and salts of isomers;

(ii) 8-chloro-6-(2-fluorophenyl)-1-methyl-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*α*][1,4]diazepine (other name: flualprazolam), its salts, isomers, and salts of isomers;

(iii) 6-(2-chlorophenyl)-1-methyl-8-nitro-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*α*][1,4]diazepine (other name: clonazolam), its salts, isomers, and salts of isomers;

(iv) 8-bromo-6-(2-fluorophenyl)-1-methyl-4*H*-benzo[*f*][1,2,4]triazolo [4,3-*α*][1,4]diazepine (other name flubromazolam), its salts, isomers, and salts of isomers;

(v) 7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2*H*-benzo[*e*][1,4]diazepin-2-one (other name: diclazepam), its salts, isomers, and salts of isomers; and

(vi) 8-bromo-1-methyl-6-phenyl-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*α*][1,4]diazepine other name: bromazolam) including its salts, isomers, and salts of isomers.

(i) Precursor chemicals:

(i) *N*-(1-benzylpiperidin-4-yl)-*N*-phenylpropionamide (other name: benzylfentanyl) and its salts;

(ii) *N*-phenylpiperidin-4-amine (other names: 4-anilinopiperidine; *N*-phenyl-4-piperidinamine; 4-AP), and its amides, carbamates, halides, salts, and any combination thereof, whenever the existence of such is possible;

(iii) 3,4-MDP-2-P methyl glycidate (PMK glycidate) and its optical and geometric isomers;

(iv) 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its salts, optical and geometric isomers; and

(v) Alpha-phenylacetoacetamide (APAA) and its optical isomers.

Chapter 1

Additional Controlled Substances

Emergency rules are in effect no longer than 120 days after filing with the Registrar of Rules.

Section 1. Purpose. The purpose of these rules is to add, delete, and reschedule controlled substances in the Wyoming Controlled Substances Act of 1971. Some changes will be made to similarly control a substance in response to the publication of a final order in the Federal Register designating that substance as a controlled substance under federal law. Other changes will be made at the discretion of the Wyoming Attorney General, in his or her capacity as the Commissioner of Drugs and Substances Control, with the advice of the Advisory Board on Drugs and Substances Control.

Section 2. Authority. The Commissioner of Drugs and Substances Control's rulemaking authority is found at Wyoming Statute § 35-7-1011(a) and (d), which allow the Commissioner to add, delete, and reschedule substances to the control schedules pursuant to the procedures of the Wyoming Administrative Procedure Act.

Section 3. Additional Controlled Substances. The Commissioner of Drugs and Substances Control adds the following substances to Schedule I:

(a) Synthetic cannabinoids:

(i) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, commonly known as 5F-AMB, and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(ii) [N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide, commonly known as ADB-FUBINACA;

(iii) [Methyl 2-(1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl)amino]-3-methylbutanoate], commonly known as FUB-AMB;

(iv) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, commonly known as NM2201; CBL2201, and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(v) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 4-CN-CUMYL-BUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA; CUMYL-4CN-BINACA; SGT-78, and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(vi) methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-CHMICA, AMB-CHMICA, and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(vii) 1-(5-fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*-pyrrolo[2,3-*b*]pyridine-3-carboxamide, commonly known as 5F-CUMYL-P7AICA, and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(viii) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide, commonly known as MAB-CHMINACA or ADB-CHMINACA, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible;

(ix) methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-ADB or 5F-MDMB-PINACA;

(x) methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as MDMB-CHMICA or MMB-CHMINACA;

(xi) methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as MDMB-FUBINACA;

(xii) ethyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-EDMB-PINACA, and its optical, positional, and geometric isomers, salts, and salts of isomers;

(xiii) methyl 2-(1-(5-fluoropentyl)-1*H*-indole-3-carboxamido)-3,3-dimethylbutanoate commonly known as 5F-MDMB-PICA, and its optical, positional, and geometric isomers, salts, and salts of isomers;

(xiv) *N*-(adamantan-1-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamide, commonly known as FUB-AKB48; FUB-APINACA; AKB48 *N*-(4-FLUOROBENZYL), and its optical, positional, and geometric isomers, salts, and salts of isomers;

(xv) 1-(5-fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*-indazole-3-carboxamide commonly known as 5F-CUMYL-PINACA; SGT-25, and its optical, positional, and geometric isomers, salts, and salts of isomers;

(xvi) (1-(4-fluorobenzyl)-1*H*-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone commonly known as FUB-144, and its optical, positional, and geometric isomers, salts, and salts of isomers;

(xvii) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1*H*-indazole-3-carboxamide (other name: 5F-AB-PINACA) and its salts, isomers, and salts of isomers;

(xviii) methyl 2-(1-(4-fluorobutyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate (other name: 4F-MDMB-BINACA, 4F-MDMB-BUTINACA) and its salts, isomers, and salts of isomers;

(xix) methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1*H*-indazole-3-carboxamido)butanoate (other name: MDMB-4en-PINACA) and its optical and geometric isomers, salts, and salts of isomers, whenever the existence of such isomers and salts is possible;

(xx) methyl 2-[[1-(4-fluorobutyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (other names: 4F-MDMB-BUTICA; 4F-MDMB-BICA) and its optical and geometric isomers, salts, and salts of isomers, whenever the existence of such isomers and salts is possible;

(xxi) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1-yl)-1*H*-indazole-3-carboxamide (other name: ADB-4en-PINACA) and its optical and geometric isomers, salts, and salts of isomers, whenever the existence of such isomers and salts is possible;

(xxii) 5-Pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-*b*]indol-1-one (other names: CUMYL-PEGACLONE; SGT—151) and its optical and geometric isomers, salts, and salts of isomers, whenever the existence of such isomers and salts is possible;

(xxiii) ethyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (other names: 5F-EDMB-PICA; 5F-EDMB-2201) and its optical and geometric isomers, salts, and salts of isomers, whenever the existence of such isomers and salts is possible; and

(xiv) methyl 2-(1-(4-fluorobenzyl)-1*H*-indole-3-carboxamido)-3-methylbutanoate (other name: MMB-FUBICA) and its optical and geometric isomers, salts, and salts of isomers, whenever the existence of such isomers and salts is possible.

(b) Synthetic opioid analgesics:

(i) trans-3,4-dichloro-*N*-[2-dimethylamino)cyclohexyl]-*N*-methylbenzamide, commonly known as U-47700;

(ii) para-fluorobutyryl fentanyl, commonly known as p-FBF;

(iii) *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacetamide, commonly known as acetyl fentanyl;

(iv) 3,4-dichloro-*N*-[(1dimethylamino)cyclohexylmethyl]benzamide), commonly known as AH-7921;

(v) Cyclopentyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylcyclopentanecarboxamine) including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(vi) Isobutyryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylisobutyramide) including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(vii) *para*-Chloroisobutyryl fentanyl (*N*-(4-chlorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide) including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(viii) *para*-Methoxybutyryl fentanyl (*N*-(4-methoxyphenyl)-*N*-(1-phenethylpiperidin-4-yl)butyramide) including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible; and

(ix) Valeryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylpentanamide) including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible.

(c) Analgesics:

(i) 4-chloro-*N*-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-benzenesulfonamide, commonly known as W-18.

(d) Synthetic opioids:

(i) *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutyramide, also known as *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutanamide, (commonly known as butyryl fentanyl);

(ii) *N*-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-*N*-phenylpropanamide, also known as *N*-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-*N*-phenylpropanamide, (commonly known as beta-hydroxythiofentanyl) and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(iii) *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylfuran-2-carboxamide, (commonly known as furanyl fentanyl) and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(iv) *para*-fluoroisobutyryl fentanyl [*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide] (commonly known as 4-fluoroisobutyryl fentanyl) and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(v) acryloylfentanyl [*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacrylamide], (commonly known as acryl fentanyl) and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(vi) [N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide], (commonly known as tetrahydrofuranyl fentanyl) and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(vii) [N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide], (commonly known as ocfentanil) and its isomers, ethers, salts, and salts of isomers, esters, and ethers;

(viii) Cyclopropyl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide] and its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;

(ix) Methoxyacetyl fentanyl [2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide] and its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;

(x) *ortho*-Fluorofentanyl [N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide] (also known as 2-fluorofentanyl) and its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;

(xi) *para*-Fluorobutyl fentanyl [N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide] and its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;

(xii) Fentanyl related substances that are not currently listed in any schedule of the Wyoming Controlled Substances Act and their isomers, ethers, salts, and salts of isomers, esters, and ethers;

(xiii) *N, N*-diethyl-2-[2-(4 isopropoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl]ethan-1-amine (commonly known as isotonitazene), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xiv) Crotonyl fentanyl [(*E*)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide];

(xv) 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2*H*-benzo[*d*]imidazole-2-one, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other names: bromphine; 1-[1-[1-(4-bromophenyl)ethyl]-4-piperidinyl]-1,3-dihydro-2*H*-benzimidazol-2-one);

(xvi) *beta*-Methyl fentanyl (*N*-phenyl-*N*-(1-(2-phenylpropyl)piperidin-4-yl)propionamide; also known as β -methyl fentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xvii) *beta'*-Phenyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*,3-diphenylpropanamide; also known as β' -phenyl fentanyl; 3-phenylpropanoyl fentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xviii) 2'-Fluoro *ortho*-fluorofentanyl (*N*-(1-(2-fluorophenethyl)piperidin-4-yl)-*N*-(2-fluorophenyl)propionamide; also known as 2'-fluoro 2-fluorofentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xix) 4'-Methyl acetyl fentanyl (*N*-(1-(4-methylphenethyl)piperidin-4-yl)-*N*-phenylacetamide) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xx) *ortho*-Fluorobutyryl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)butyramide; also known as 2-fluorobutyryl fentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxi) *ortho*-Methyl acetylfentanyl (*N*-(2-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)acetamide; also known as 2-methyl acetylfentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxii) *ortho*-Methyl methoxyacetyl fentanyl (2-methoxy-*N*-(2-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)acetamide; also known as 2-methyl methoxyacetyl fentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxiii) *para*-Methylfentanyl (*N*-(4-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)propionamide; also known as 4-methylfentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxiv) Phenyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbenzamide; also known as benzoyl fentanyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxv) Thiofuranyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylthiophene-2-carboxamide; also known as 2-thiofuranyl) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxvi) Fentanyl carbamate (ethyl (1-phenethylpiperidin-4-yl)(phenyl)carbamate) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxvii) *ortho*-Fluoroacryl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)acrylamide) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxviii) *ortho*-Fluoroisobutyryl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxix) *para*-Fluoro furanyl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)furan-2-carboxamide) and its isomers, esters, ethers, salts and salts of isomers, esters and ethers;

(xxx) 2-(2-(4-butoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (other name: Butonitazene);

(xxxi) 2-(2-(4-ethoxybenzyl)-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: Etodesnitazene; etazene);

(xxxii) *N,N*-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Flunitazene);

(xxxiii) *N,N*-diethyl-2-(2-(4-methoxybenzyl)-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Metodesnitazene);

(xxxiv) *N,N*-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Metonitazene);

(xxxv) 2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1*H*-benzimidazole, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: *N*-pyrrolidino etonitazene; etonitazepyne);

(xxxvi) *N,N*-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Protonitazene);

(xxxvii) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation;

(xxxviii) *meta*-fluorofentanyl (*N*-(3-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)propionamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xxxix) *meta*-fluoroisobutyryl fentanyl (*N*-(3-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xl) *para*-methoxyfuranyl fentanyl (*N*-(4-methoxyphenyl)-*N*-(1-phenethylpiperidin-4-yl)furan-2-carboxamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xli) 3-furanyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylfuran-3-carboxamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xlii) 2',5'-dimethoxyfentanyl (*N*-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-*N*-phenylpropionamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xliii) isovaleryl fentanyl (3-methyl-*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutanamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xliv) *ortho*-fluorofuranyl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)furan-2-carboxamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xlv) *alpha*'-methyl butyryl fentanyl (2-methyl-*N*-(1-phenethylpiperidin-4-yl)-*N*-penylbutanamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xlvi) *para*-methylcyclopropyl fentanyl (*N*-(4-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xlvii) 1-(2-methyl-4(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one (commonly known as 2-methyl AP-237), including its optical and geometric isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible;

(xlviii) 2-(4-methoxybenzyl)-5-nitro-1-(2-(pyrrolidine-1-yl)-1*H*-benzimidazole, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: *N*-pyrrolidino metonitazene; metonitazepyne);

(xlix) 5-nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidine-1-yl)ethyl)-1*H*-benzimidazole, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: *N*-pyrrolidino protonitazene; protonitazepyne);

(l) *N*-ethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: *N*-desethyl isetonitazene);

(li) 2-(4-ethoxybenzyl)-5-nitro-1-(2-(piperidin-1-yl)ethyl)-1*H*-benzimidazole, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: *N*-piperidinyl etonitazene; etonitazepipine);

(lii) 2-(2-((2,3-dihydrobenzofuran-5-yl)methyl)-5-nitro-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Ethyleneoxynitazene);

(liii) 2-(2-(benzodioxol-5-ylmethyl)-5-nitro-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: Methylenedioxyntazene; 3',4'-methylenedioxyntazene);

(liv) 2-(2-(4-ethoxybenzyl)-5-methyl-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: 5-methyl etodesnitazene);

(lv) 2-(2-(4-ethoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)-*N*-ethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: *N*-desethyl etonitazene);

(lvi) *N*-ethyl-2-(5-nitro-2-(4-propoxybenzyl)-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: *N*-desethyl protonitazene);

(lvii) 2-(2-(4-ethoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)-*N,N*-dimethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other Name: *N,N*-dimethylamino etonitazene); and

(lviii) 2-(4-isopropoxybenzyl)-5-nitro-1-(20(pyrrolidine-1-yl)ethyl)-1*H*-benzimidazole, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: *N*-pyrrolidino isotonitazene).

(e) Synthetic cathinone:

(i) *N*-1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone, commonly known as *N*-ethylpentylone, ephylone, and its optical, positional, and geometric isomers, salts, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible;

(ii) *N*-Ethylhexedrone (other name: 2-(ethylamino)-1-phenylhexan-1-one) and its optical, positional, and geometric isomers, salts, and salts of isomers;

(iii) alpha-Pyrrolidinohexanophenone (other names: a-PHP; alpha-pyrrolidinohexiophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one) and its optical, positional, and geometric isomers, salts, and salts of isomers;

(iv) 4-Methyl-alpha-ethylaminopentiophenone (other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one) and its optical, positional, and geometric isomers, salts, and salts of isomers;

(v) 4'-Methyl-alpha-pyrrolidinohexiophenone (other names: MPHP; 4'-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)heptan-1-one) and its optical, positional, and geometric isomers, salts, and salts of isomers;

(vi) alpha-Pyrrolidinoheptaphenone (other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one) and its optical, positional, and geometric isomers, salts, and salts of isomers;

(vii) 4'-Chloro-alpha-pyrrolidinovalerophenone (other names: 4-chloro-a-PVP; 4'-chloro-alpha-pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one) and its optical, positional, and geometric isomers, salts, and salts of isomers;

(viii) 4-methyl-N-ethylcathinon (other name: 4-MEC) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(ix) 4-methyl-alpha-pyrrolidinopropiophenone (other name: 4-MePPP) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(x) alpha-pyrrolidinopentiophenone (other name: α -PVP) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(xi) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (other names: butylone, bk-MBDB) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(xii) 2-(methylamino)-1-phenylpentan-1-one (other name: pentedron) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(xiii) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (other names: pentylone, bk-MBDP) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(xiv) 4-fluoro-N-methylcathinone (other names: 4-FMC, flephedrone) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(xv) 3-fluoro-N-methylcathinone (other name: 3-FMC) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(xvi) 1-(naphthalene-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (other name: naphyrone) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible; and

(xvii) α -pyrrolidinobutiophenon (other name: α -PBP) and its optical, positional, and geometric isomers, salts, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible.

(f) Hallucinogenic substances:

(i) 1-(4-methoxyphenyl)-*N*-methylpropan-2-amine (other names: *para*-methoxymethamphetamine, PMMA), including its salts, isomers, and salts of isomers;

(ii) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine, MXE);

(iii) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one (other names: eutylone; bk-EBDB);

(iv) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1*H*-indazole-3-carboxamide (also known as ADB-BUTINACA), including its salts, isomers, and salts of isomers;

(v) 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (also known as α -PiHP or *alpha*-PiHP), including its salts, isomers, and salts of isomers;

(vi) 2-(methylamino)-1-(3-methylphenyl)propan-1-one (also known as 3-MMC or 3-methylmethcathinone), including its salts, isomers, and salts of isomers; ~~and~~

(vii) 4-Chloromethcathinone (also known as 4—CMC or 1-(4-chlorophenyl)-2-(methylamino)propan-1-one), including its salts, isomers, and salts of isomers; and

(viii) 3-methoxyphencyclidine (other names: 1-(1-(3-methoxyphenyl)cyclohexyl)piperidine; 3-MeO-PCP), including its salts, isomers, and salts of isomers.

(g) Stimulants:

(i) 4,4'-Dimethylaminorex (common name 4,4'-DMAR; other names 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine);

(ii) Amineptine (7-[(10,11-dihydro-5*H*-dibenzo[*a,d*]cyclohepten-5-yl)amino]heptanoic acid), including its salts, isomers, and salts of isomers;

(iii) Mesocarb (*N*-phenyl-*N'*-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimide), including its salts, isomers, and salts of isomers;

(iv) Methiopropamine (*N*-methyl-1-(thiophen-2-yl)propan-2-amine), including its salts, isomers, and salts of isomers; ~~and~~

(v) Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate), including its salts, isomers, and salts of isomers; and

(vi) 4-Fluoroamphetamine (4-FA, 1-(4-fluorophenyl)propan-2-amine, *para*-fluoroamphetamine, including its salts, isomers, and salts of isomers.

(h) Depressants:

(i) 4-(2-chlorophenyl)-2-ethyl-9-methyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine (other name: etizolam), its salts, isomers, and salts of isomers;

(ii) 8-chloro-6-(2-fluorophenyl)-1-methyl-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine (other name: flualprazolam), its salts, isomers, and salts of isomers;

(iii) 6-(2-chlorophenyl)-1-methyl-8-nitro-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine (other name: clonazolam), its salts, isomers, and salts of isomers;

(iv) 8-bromo-6-(2-fluorophenyl)-1-methyl-4*H*-benzo[*f*][1,2,4]triazolo [4,3-*a*][1,4]diazepine (other name flubromazolam), its salts, isomers, and salts of isomers; ~~and~~

(v) 7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2*H*-benzo[*e*][1,4]diazepin-2-one (other name: diclazepam), its salts, isomers, and salts of isomers; and

(vi) 8-bromo-1-methyl-6-phenyl-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine other name: bromazolam) including its salts, isomers, and salts of isomers.

(i) Precursor chemicals:

(i) *N*-(1-benzylpiperidin-4-yl)-*N*-phenylpropionamide (other name: benzylfentanyl) and its salts;

(ii) *N*-phenylpiperidin-4-amine (other names: 4-anilinopiperidine; *N*-phenyl-4-piperidinamine; 4-AP), and its amides, carbamates, halides, salts, and any combination thereof, whenever the existence of such is possible;

(iii) 3,4-MDP-2-P methyl glycidate (PMK glycidate) and its optical and geometric isomers;

(iv) 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its salts, optical and geometric isomers; and

(v) Alpha-phenylacetoacetamide (APAA) and its optical isomers.